ArticleCureus2025
Correlation of Vascular Calcification With Frailty and Quality of Life in Chronic Kidney Disease Stage 4 and 5 Non-dialysis Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimVascular calcification (VC) is known to be associated with higher cardiovascular risk in chronic kidney disease (CKD). However, its impact on morbidity factors like frailty and quality of life is understudied. This study aims to address this gap by assessing the correlation of VC with frailty and quality of life.
methodsConsecutive patients with CKD stage 4 and 5, not on dialysis, were enrolled over one year. Pregnant patients and renal transplant recipients were excluded. VC was assessed using lateral abdominal radiographs, echocardiography, and cardiac computed tomography scans. Frailty was assessed using the Fried frailty phenotype. A Kidney Disease Quality of Life-36 (KDQoL-36
resultsA total of 202 patients were enrolled, of which, 26% of patients had detectable VC. Older age, smoking, and coronary artery disease were associated with higher prevalence of VC. Stage of CKD or mineral bone disease markers did not show any significant difference between patients with and without VC. Individuals with VC were significantly more likely to be frail than those without (57.4% vs 30.4%, p-value- 0.001). Patients with VC had significantly lower quality of life scores as compared to those without VC (physical component scores - 45.84±18.98 vs 62.34±22.06; mental component scores - 51.18±20.17 vs 65.99±23.75; kidney disease component scores - 64.90±13.65 vs 74.28±16.32, p-value <0.001).
conclusionPatients with VC showed higher prevalence of frailty and significantly impaired quality of life. This highlights the profound clinical implications of VC on functional decline in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.